Zacks Research Issues Optimistic Outlook for PBYI Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research increased their Q4 2025 earnings per share (EPS) estimates for Puma Biotechnology in a research note issued on Wednesday, January 22nd. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.16 per share for the quarter, up from their previous estimate of $0.13. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.01 EPS and Q3 2026 earnings at $0.11 EPS.

Several other research analysts have also recently weighed in on PBYI. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Stock Performance

Shares of PBYI opened at $2.96 on Friday. The firm has a market cap of $145.31 million, a P/E ratio of 6.17 and a beta of 1.10. Puma Biotechnology has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The firm’s 50 day moving average price is $3.06 and its two-hundred day moving average price is $2.99.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million for the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter in the previous year, the business posted $0.12 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PBYI. Gateway Wealth Partners LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth about $31,000. SG Americas Securities LLC bought a new stake in shares of Puma Biotechnology during the 3rd quarter worth approximately $34,000. Franklin Resources Inc. acquired a new stake in shares of Puma Biotechnology during the 3rd quarter worth approximately $41,000. Dynamic Technology Lab Private Ltd bought a new position in Puma Biotechnology in the third quarter valued at approximately $44,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Puma Biotechnology during the second quarter valued at approximately $58,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Insiders Place Their Bets

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 23.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.